Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
about
Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigmaNew advances in DPYD genotype and risk of severe toxicity under capecitabine.Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.The molecular basis of rectal cancer.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseAssociation between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
P2860
Q28596636-6E330217-9499-4093-B90D-5551877CB0F8Q33648195-5BC93ABC-B76B-4C88-AE65-DAC9946530FFQ34550417-C75EDA8C-4825-433D-818D-FC1B02C887AFQ35109123-C7D53E6C-D624-4366-BE06-08520691E758Q35585759-6939CB2D-9BDD-4426-8775-248EF0B47191Q36535211-BFF337BF-465C-43FF-BF6D-194E34028F53Q37042575-D73D3C11-E74B-4B22-8FFD-031DE07F4DB5Q37685527-6A303134-E3DB-48F0-9BEF-053D40F5AC9EQ39470148-80943D12-41F8-4008-9DB0-B548C0BA9C79Q45980539-D2E217C2-A1E6-4F1A-89B3-9CF7CBD04092Q47123004-B2B5D999-1E82-4F48-B5A7-4D5B490610EFQ47135784-C335D12D-F196-43D1-AADB-70334B01CB91
P2860
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@en
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@nl
type
label
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@en
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@nl
prefLabel
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@en
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@nl
P2093
P2860
P356
P1476
Clinical importance of risk va ...... set fluoropyrimidine toxicity.
@en
P2093
Markus Joerger
Tanja K Froehlich
Ursula Amstutz
P2860
P304
P356
10.1002/IJC.29025
P577
2014-06-27T00:00:00Z